专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2010111449A1 INTRAOCULAR SUSTAINED RELEASE DRUG DELIVERY SYSTEMS AND METHODS FOR TREATING OCULAR CONDITIONS 审中-公开
标题翻译：内部持续释放药物输送系统及治疗眼睛病症的方法
公开(公告)号：WO2010111449A1
公开(公告)日：2010-09-30
申请号：PCT/US2010/028584
申请日：2010-03-25
申请人： ALLERGAN, INC. , ROBINSON, Michael R. , BURKE, James A. , LIU, Hui , ORILLA, Werhner C. , SPADA, Lon T. , WHITCUP, Scott , GHEBREMESKEL, Alazar N. , HUGHES, Patrick M. , XU, Kun , DO, Marianne M.
发明人： ROBINSON, Michael R. , BURKE, James A. , LIU, Hui , ORILLA, Werhner C. , SPADA, Lon T. , WHITCUP, Scott , GHEBREMESKEL, Alazar N. , HUGHES, Patrick M. , XU, Kun , DO, Marianne M.
IPC分类号： A61K31/5575 , A61K31/557 , A61P27/06 , A61K9/00 , A61K9/16 , A61K9/20 , A61K47/34
CPC分类号： A61K31/557 , A61K9/0051 , A61K9/1647 , A61K9/70 , A61K31/00 , A61K31/5575
摘要： Biocompatible, bioerodible sustained release implants and microspheres for intracameral or anterior vitreal placement include an anti-hypertensive agent and a biodegradable polymer effective to treat an ocular hypertensive condition (such as glaucoma) by relapsing therapeutic amount of the anti-hypertensive agent over a period of time between 10 days and 1 year.
摘要翻译：生物相容性，生物可蚀性缓释植入物和用于乳房内或玻璃体前置放置的微球包括抗高血压剂和可生物降解的聚合物，其通过在一段时间内复发治疗量的抗高血压药物而有效治疗眼高血压病症（如青光眼）时间在10天到1年之间。

2. 发明申请

WO2010062523A2 PROSTAGLANDIN AND PROSTAMIDE DRUG DELIVERY SYSTEMS AND INTRAOCULAR THERAPEUTIC USES THEREOF 审中-公开
标题翻译：前列腺素和前列腺药物递送系统及其眼内治疗用途
公开(公告)号：WO2010062523A2
公开(公告)日：2010-06-03
申请号：PCT/US2009/061798
申请日：2009-10-23
申请人： ALLERGAN, INC. , ROBINSON, Michael R. , LIU, Hui , HUGHES, Patrick M. , SPADA, Lon T. , GHEBREMESKEL, Alazar N.
发明人： ROBINSON, Michael R. , LIU, Hui , HUGHES, Patrick M. , SPADA, Lon T. , GHEBREMESKEL, Alazar N.
IPC分类号： A61K9/00 , A61K9/16 , A61K9/20 , A61K31/557 , A61K31/5575 , A61P27/06
CPC分类号： A61L31/06 , A61K9/0048 , A61K9/0051 , A61K9/1647 , A61K9/204 , A61K31/216 , A61K31/557 , A61K31/5575 , A61L31/16
摘要： Biocompatible, bioerodible implants and microspheres include latanoprost and a biodegradable polymer effective, when placed intraocular (such as into the subtenon space) to treat glaucoma.
摘要翻译：生物相容性生物蚀解性植入物和微球体包括拉坦前列素和可生物降解的聚合物，当置于眼内时（例如进入眼球下区）治疗青光眼。

3. 发明申请

WO2011127064A3 SUSTAINED-RELEASE RESERVOIR IMPLANTS FOR INTRACAMERAL DRUG DELIVERY 审中-公开
公开(公告)号：WO2011127064A3
公开(公告)日：2011-10-13
申请号：PCT/US2011/031265
申请日：2011-04-05
申请人： ALLERGAN, INC. , SHI, Ruwen , HUGHES, Patrick M. , BURKE, James A. , ROBINSON, Michael R. , LIU, Hui
发明人： SHI, Ruwen , HUGHES, Patrick M. , BURKE, James A. , ROBINSON, Michael R. , LIU, Hui
IPC分类号： A61K9/00
摘要： The present invention provides a sustained release implant for intraocular use to treat elevated intraocular pressure, which implant is configured for intracameral or anterior vitreal administration to a patient with elevated intraocular pressure (IOP), said implant comprising a core of an antihypertensive agent surrounded by a polymer, which limits the rate of passage of the antihypertensive agent from the implant into the eye of said patient and said implant provides a linear rate of release of therapeutically effective amounts of said anti-hypertensive agent into the eye for a period of time of between 14 days and 365 days.

4. 发明申请

WO2008019267A2 OCULAR IMPLANT DELIVERY ASSEMBLIES WITH DISTAL CAPS 审中-公开
标题翻译： OCULAR IMPLANT交付组件与远端CAPS
公开(公告)号：WO2008019267A2
公开(公告)日：2008-02-14
申请号：PCT/US2007/074937
申请日：2007-08-01
申请人： ALLERGAN, INC. , TROGDEN, John T. , LYONS, Robert T. , CHANG, James N. , ROBINSON, Michael R. , ORILLA, Werhner C.
发明人： TROGDEN, John T. , LYONS, Robert T. , CHANG, James N. , ROBINSON, Michael R. , ORILLA, Werhner C.
IPC分类号： A61F9/00
CPC分类号： A61F9/0017 , A61K9/0051
摘要： Ocular implant delivery assemblies are provided which include a cannula having a lumen extending therethrough, a proximal end, a proximal end opening, a distal end, a distal end opening, and a lumen extending through the cannula. A cap is provided having a closed distal end, being in contact with the outer wall of the cannula, and covering the distal end and the distal end opening of the cannula, the cap being structured to allow the distal end and the distal end opening of the cannula to pass through the cap as the cannula is passed into an eye. An ocular implant is located in the lumen. The implant may be sealed in the cannula without the addition of a liquid carrier or it may be contained in a liquid carrier medium in the cannula. The implant may be made up of a number of microparticles having different compositions or different forms. The assembly also includes a sleeve located on the proximal end of the cannula and suitable for coupling the assembly to a syringe containing a pushing gel.
摘要翻译：提供了眼部植入物递送组件，其包括具有延伸穿过其中的内腔的套管，近端，近端开口，远端，远端开口和延伸穿过套管的内腔。提供具有封闭的远端的盖，其与套管的外壁接触并且覆盖套管的远端和远端开口，帽被构造成允许远端和远端开口当套管穿过眼睛时，套管穿过帽子。眼内植入物位于内腔中。植入物可以密封在套管中而不加入液体载体，或者其可以包含在插管中的液体载体介质中。植入物可以由具有不同组成或不同形式的许多微粒组成。组件还包括位于套管的近端上的套筒，并且适于将组件耦合到包含推动凝胶的注射器。

5. 发明申请

WO2011091205A2 INTRACAMERAL SUSTAINED RELEASE THERAPEUTIC AGENT IMPLANTS 审中-公开
标题翻译：内镜持续释放治疗代理植入物
公开(公告)号：WO2011091205A2
公开(公告)日：2011-07-28
申请号：PCT/US2011/021971
申请日：2011-01-21
申请人： ALLERGAN, INC. , ROBINSON, Michael R. , BURKE, James , SCHIFFMAN, Rhett
发明人： ROBINSON, Michael R. , BURKE, James , SCHIFFMAN, Rhett
IPC分类号： A61K9/00
CPC分类号： A61K9/0051 , A61K9/0024 , A61K9/1647 , A61K31/5575 , A61K47/10 , A61K47/34 , A61L27/18 , A61L27/54 , A61L27/58
摘要： Described herein are intracameral implants including at least one therapeutic agent for treatment of at least one ocular condition. The implants described herein are not anchored to the ocular tissue, but rather are held in place by currents and gravity present in the anterior chamber of an eye. The implants are preferably polymeric, biodegradable and provide sustained release of at least one therapeutic agent to both the trabecular meshwork and associated ocular tissue and the fluids within the anterior chamber of an eye.
摘要翻译：本文描述的是包括用于治疗至少一种眼部病症的至少一种治疗剂的植入物植入物。本文所述的植入物不固定在眼组织上，而是通过存在于眼前房中的电流和重力保持在适当位置。植入物优选是聚合的，可生物降解的并且提供至少一种治疗剂持续释放到小梁网和相关联的眼组织和眼睛前房内的流体。

6. 发明申请

WO2013101954A1 3-PHENYL-5-UREIDOISOTHIAZOLE-4-CARBOXIMIDE AND 3-AMINO-5-PHENYLISOTHIAZOLE DERIVATIVES AS KINASE INHIBITORS 审中-公开
标题翻译：作为激酶抑制剂的3-苯基-5-尿嘧啶-4-氧羰酰胺和3-氨基-5-苯并噻唑衍生物
公开(公告)号：WO2013101954A1
公开(公告)日：2013-07-04
申请号：PCT/US2012/071855
申请日：2012-12-27
申请人： ALLERGAN, INC. , MALONE, Thomas C. , HULL, Clarence, E., III , BORAL, Sougato , WURSTER, Julie A. , EDELMAN, Jeffrey L. , ROBINSON, Michael R.
发明人： MALONE, Thomas C. , HULL, Clarence, E., III , BORAL, Sougato , WURSTER, Julie A. , EDELMAN, Jeffrey L. , ROBINSON, Michael R.
IPC分类号： C07D417/12 , C07D295/13 , C07D275/03 , A61K31/425 , A61K31/427 , A61P35/00 , A61P3/00
CPC分类号： C07D417/12 , C07D275/03 , C07D295/13
摘要： This invention is directed to a compound of Formula I Formula I or a pharmaceutically acceptable salt thereof, wherein R, R 1 , R 2 , R 3 , n, X 1 , X 2 , L 1 , and L 2 are as defined herein. The compounds of Formula I are useful as receptor tyrosine kinase (RTK) inhibitors and can be used to treat such diseases as cancer, blood vessel proliferative disorders, fibrotic disorders, mesangial cell proliferative disorders and metabolic diseases.
摘要翻译：本发明涉及式I化合物或其药学上可接受的盐，其中R，R 1，R 2，R 3，n，X 1，X 2，L 1和L 2如本文所定义。式I化合物可用作受体酪氨酸激酶（RTK）抑制剂，可用于治疗癌症，血管增生性疾病，纤维化病症，肾小球膜细胞增殖性疾病和代谢疾病等疾病。

7. 发明申请

WO2014052518A1 BIODEGRADABLE DRUG DELIVERY SYSTEMS FOR THE SUSTAINED RELEASE OF PROTEINS 审中-公开
标题翻译：用于持续释放蛋白质的生物可降解药物输送系统
公开(公告)号：WO2014052518A1
公开(公告)日：2014-04-03
申请号：PCT/US2013/061803
申请日：2013-09-26
申请人： ALLERGAN, INC.
发明人： WU, Cindy W. , ROBINSON, Michael R. , BURKE, James A. , HUGHES, Patrick M.
IPC分类号： A61K36/00 , A61K9/00 , A61K47/34 , A61K9/70
CPC分类号： A61K9/0051 , A61F9/0017 , A61K39/3955 , A61K47/34
摘要： Biodegradable drug delivery systems, such as extruded implants, for the sustained delivery of a protein to an ocular region of the eye or intraarticular region in the body are described. The drug delivery systems may be used to treat a variety of ocular and medical conditions, including macular degeneration. Methods for using and making the drug delivery systems are also described. The drug delivery systems can be in the form of extruded filaments configured for placement in an ocular region such as the vitreous body or anterior chamber of the eye.
摘要翻译：描述了用于将蛋白质持续递送至眼睛的眼部区域或体内关节内区域的可生物降解的药物递送系统，例如挤出植入物。药物递送系统可用于治疗各种眼部和医学状况，包括黄斑变性。还描述了使用和制备药物递送系统的方法。药物递送系统可以是被配置用于放置在诸如眼睛的玻璃体或前房的眼部区域中的挤出细丝的形式。

8. 发明申请

WO2015130945A1 INTRAOCULAR IMPLANT DELIVERY APPARATUS AND METHODS OF USE THEREOF 审中-公开
标题翻译：内窥镜输送装置及其使用方法
公开(公告)号：WO2015130945A1
公开(公告)日：2015-09-03
申请号：PCT/US2015/017779
申请日：2015-02-26
申请人： ALLERGAN, INC.
发明人： NOVAKOVIC, Zoran , BHAGAT, Rahul , DAVIS, Shawn R. , MUCIENTES, David , ROBINSON, Michael R. , VOJAN, Vaclav , STREHL, Michael , MICHAELIS, Ina , VOGL, Maximilian , KREHER, Jessica
IPC分类号： A61F9/007 , A61F9/00
CPC分类号： A61M5/158 , A61F9/0008 , A61F9/00781
摘要： Apparatus (40) and methods for introducing a solid or semi-solid intraocular drug-containing implant (68) into the anterior chamber of an eye are described. The drug-containing implant can be a rod-shaped biodegradable implant that may provide for the extended release of the drug and may be effective for treating a medical condition of the eye. The apparatus is economically designed in the shape or style of a pen with tactile surfaces for easy gripping, a needle-rotation knob (52) to permit orientation of the needle (56) bevel in relation to the eye, and a spring-actuated mechanism for consistent deployment of the implant.
摘要翻译：描述了用于将固体或半固体眼内药物植入物（68）引入眼睛前房的装置（40）和方法。含药物的植入物可以是棒状可生物降解的植入物，其可以提供药物的延长释放，并且可以有效治疗眼睛的医疗状况。该设备经济地设计成具有易于抓握的触觉表面的笔的形状或风格，允许针（56）相对于眼睛的倾斜方向的针旋转旋钮（52）以及弹簧致动机构用于植入物的一致部署。

9. 发明申请

WO2014143754A2 PROSTAMIDE-CONTAINING INTRAOCULAR IMPLANT 审中-公开
标题翻译：含前列腺炎的人工种植体
公开(公告)号：WO2014143754A2
公开(公告)日：2014-09-18
申请号：PCT/US2014/027851
申请日：2014-03-14
申请人： ALLERGAN, INC.
发明人： HUGHES, Patrick M. , SHEN, Jie , ROBINSON, Michael R. , WOODWARD, David F. , BURK, Robert M. , LIU, Hui , WAN, Jinping , DURAIRAJ, Chandrasekar , AMBRUS, Gyorgy F. , WU, Ke , DINH, Danny T.
IPC分类号： A61L27/18
CPC分类号： A61K31/559 , A61F9/0017 , A61F9/00781 , A61K9/0051 , A61K9/146 , A61K31/381 , A61K47/34 , A61L27/18 , A61L27/54 , A61L27/58 , A61L2430/16 , C08L67/04
摘要： Prostamide-containing biodegradable intraocular implants, prostamide compounds, prostamide-containing pharmaceutical compositions, and methods for making and using such implants and compositions for the immediate and sustained reduction of intraocular pressure and treatment of glaucoma in an eye of a patient are described.
摘要翻译：含有含有前列腺酰胺的可生物降解的眼内植入物，前列酰胺化合物，含有前列酰胺的药物组合物以及制备和使用这种植入物和组合物的方法，用于立即持续降低眼内压并治疗眼内青光眼描述了病人的情况。

10. 发明申请

WO2015066548A1 PROSTAMIDE-CONTAINING INTRAOCULAR IMPLANTS AND METHODS OF USE THEREOF 审中-公开
标题翻译：含有前体植入物的植入物及其使用方法
公开(公告)号：WO2015066548A1
公开(公告)日：2015-05-07
申请号：PCT/US2014/063569
申请日：2014-10-31
申请人： ALLERGAN, INC.
发明人： GHEBREMESKEL, Alazar N. , ROBINSON, Michael R.
IPC分类号： A61K9/16 , A61K47/10 , A61K47/34 , A61K31/5575
CPC分类号： A61K31/5575 , A61F9/0017 , A61K9/0051 , A61K9/1647 , A61K31/165 , A61K47/10 , A61K47/34
摘要： Prostamide-containing intraocular implants that biodegrade in the eye and that are effective for reducing intraocular pressure in an eye for a sustained period. The implants generally contain a prostamide, such as bimatoprost, and at least three distinct biodegradable polymers selected from polylactide and poly(lactide-co-glycolide) polymers and are optimized for placement in and compatibility with the anterior chamber of the eye, particularly the anterior chamber angle. Methods for making and using the implants to reduce ocular hypertension and intraocular pressure in a patient are described.
摘要翻译：在眼睛中生物降解并有效减少眼睛眼内持续持续时间的含有前列腺素的眼内植入物。植入物通常含有前列腺酰胺，例如比马前列素，以及至少三种不同的生物可降解聚合物，其选自聚丙交酯和聚（丙交酯 - 共 - 乙交酯）聚合物，并被优化用于放置在眼前房，室角度。描述了制造和使用植入物以减少患者中的高眼压和眼内压的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式